Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT05800418
- Locations
- 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China
A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05783921
- Locations
- 🇨🇳
Gansu Prouincial Cancer Hospital, Lanzhou, Gansu, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Jiangmen Central Hospital, Jiangmen, Guangdong, China
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 1946
- Registration Number
- NCT05780567
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Suining Central Hospital, Suining, Sichuan, China
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT05775575
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 89
- Registration Number
- NCT05765357
- Locations
- 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China
Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05745363
- Locations
- 🇨🇳
Affiliated Hospital Of Guilin Medical University, Guilin, Guangxi, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 570
- Registration Number
- NCT05718167
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳TianJin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Study of Polyglycan Superparamagnetic Ferric Oxide Injection on Cardiovascular Magnetic Resonance Imaging
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05687864
- Locations
- 🇨🇳
Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China
Material Balance Study of TQ-B3525
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05675202
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT05646758
- Locations
- 🇨🇳
The Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China